

Mechanism of HIV-1 Neutralization by Antibodies Targeting gp41

Journal of Virology

88, 1249-1258

DOI: [10.1128/jvi.02664-13](https://doi.org/10.1128/jvi.02664-13)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Autoreactivity in HIV-1 broadly neutralizing antibodies. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 224-234.	1.5	71
2	Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization. <i>PLoS Pathogens</i> , 2014, 10, e1004271.	2.1	54
3	Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity. <i>Journal of Virology</i> , 2014, 88, 5165-5170.	1.5	41
4	Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 1058-1067.	3.6	69
5	Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. <i>Journal of Translational Medicine</i> , 2014, 12, 346.	1.8	14
6	Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 263-270.	1.5	30
7	Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18542-18547.	3.3	67
8	Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation. <i>Journal of Biological Chemistry</i> , 2014, 289, 35015-35028.	1.6	17
9	Cholesterol-Dependent Membrane Fusion Induced by the gp41 Membrane-Proximal External Region's Transmembrane Domain Connection Suggests a Mechanism for Broad HIV-1 Neutralization. <i>Journal of Virology</i> , 2014, 88, 13367-13377.	1.5	39
10	A Fusion Intermediate gp41 Immunogen Elicits Neutralizing Antibodies to HIV-1. <i>Journal of Biological Chemistry</i> , 2014, 289, 29912-29926.	1.6	32
11	Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals. <i>Retrovirology</i> , 2014, 11, 44.	0.9	19
12	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014, 514, 455-461.	13.7	702
13	Chemically Modified Peptides Based on the Membrane-Proximal External Region of the HIV-1 Envelope Induce High-Titer, Epitope-Specific Nonneutralizing Antibodies in Rabbits. <i>Vaccine Journal</i> , 2014, 21, 1086-1093.	3.2	13
14	Antibody engineering for increased potency, breadth and half-life. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 151-159.	1.5	46
15	Elicitation of HIV-1 neutralizing antibodies by presentation of 4E10 and 10E8 epitopes on Norovirus P particles. <i>Immunology Letters</i> , 2015, 168, 271-278.	1.1	12
16	Active Targeted Drug Delivery for Microbes Using Nano-Carriers. <i>Current Topics in Medicinal Chemistry</i> , 2015, 15, 1525-1531.	1.0	17
17	Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. <i>Journal of Virology</i> , 2015, 89, 7813-7828.	1.5	35
18	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. <i>Journal of Translational Medicine</i> , 2015, 13, 60.	1.8	84

#	ARTICLE	IF	CITATIONS
19	Fusion-competent state induced by a C-terminal HIV-1 fusion peptide in cholesterol-rich membranes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 1014-1022.	1.4	12
20	Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. <i>Science</i> , 2015, 349, 191-195.	6.0	113
21	Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1192-1201.	0.5	5
22	Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody. <i>Journal of Immunology</i> , 2015, 195, 3759-3768.	0.4	4
23	Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1901.	1.8	14
24	Learning the Relationship between the Primary Structure of HIV Envelope Glycoproteins and Neutralization Activity of Particular Antibodies by Using Artificial Neural Networks. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1710.	1.8	21
25	Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. <i>Journal of Virology</i> , 2016, 90, 6127-6139.	1.5	117
26	Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. <i>Cell Host and Microbe</i> , 2016, 19, 696-704.	5.1	426
27	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016, 90, 5899-5914.	1.5	62
28	Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors. <i>Retrovirology</i> , 2016, 13, 70.	0.9	10
29	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. <i>Journal of Immunology</i> , 2016, 197, 4663-4673.	0.4	6
30	A Microâ€“Polyethylene Glycol Precipitation Assay as a Relative Solubility Screening Tool for Monoclonal Antibody Design and Formulation Development. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2319-2327.	1.6	29
31	Initiation of immune toleranceâ€“controlled HIV gp41 neutralizing B cell lineages. <i>Science Translational Medicine</i> , 2016, 8, 336ra62.	5.8	86
32	Structural basis for membrane anchoring of HIV-1 envelope spike. <i>Science</i> , 2016, 353, 172-175.	6.0	169
33	Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. <i>Science</i> , 2016, 351, 1043-1048.	6.0	402
34	HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. <i>Trends in Immunology</i> , 2016, 37, 221-232.	2.9	96
35	Engineering broadly neutralizing antibodies for HIV prevention and therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 157-173.	6.6	17
36	Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure. <i>Virology</i> , 2016, 490, 17-26.	1.1	11

#	ARTICLE	IF	CITATIONS
37	HIV-Host Interactions: Implications for Vaccine Design. <i>Cell Host and Microbe</i> , 2016, 19, 292-303.	5.1	143
38	Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10. <i>Immunity</i> , 2016, 44, 21-31.	6.6	87
39	Germline-targeting immunogens. <i>Immunological Reviews</i> , 2017, 275, 203-216.	2.8	105
40	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. <i>Scientific Reports</i> , 2017, 7, 40800.	1.6	12
41	Lipophilicity is a key factor to increase the antiviral activity of HIV neutralizing antibodies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 152, 311-316.	2.5	7
42	Peripheral Membrane Interactions Boost the Engagement by an Anti-HIV-1 Broadly Neutralizing Antibody. <i>Journal of Biological Chemistry</i> , 2017, 292, 5571-5583.	1.6	9
43	Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. <i>MBio</i> , 2017, 8, .	1.8	28
44	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	5.6	119
45	Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region. <i>Vaccine</i> , 2017, 35, 2736-2744.	1.7	3
46	Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4477-4482.	3.3	18
47	Antigp41 membrane proximal external region antibodies and the art of using the membrane for neutralization. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 250-256.	1.5	23
48	A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. <i>Virology</i> , 2017, 507, 242-256.	1.1	5
49	Eliciting 10E8-like antibodies by the membrane proximal external region peptide of HIV-1 in guinea pigs. <i>Biotechnology Letters</i> , 2017, 39, 367-373.	1.1	0
50	Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. <i>Frontiers in Immunology</i> , 2017, 8, 1154.	2.2	30
51	The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. <i>Protein and Cell</i> , 2018, 9, 596-615.	4.8	37
52	Induction of broadly neutralizing antibodies in Germinal Centre simulations. <i>Current Opinion in Biotechnology</i> , 2018, 51, 137-145.	3.3	33
53	Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions. <i>Journal of Virology</i> , 2018, 92, .	1.5	21
54	Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency. <i>Journal of Bioinformatics and Computational Biology</i> , 2018, 16, 1840007.	0.3	5

#	ARTICLE	IF	CITATIONS
55	Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 365-374.	0.5	8
56	HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 347-364.	2.3	10
57	DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity. <i>Viruses</i> , 2018, 10, 100.	1.5	11
58	Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8892-E8899.	3.3	72
59	HIV-1 Membrane-Proximal External Region Fused to Diphtheria Toxin Domain-A Elicits 4E10-Like Antibodies in Mice. <i>Immunology Letters</i> , 2019, 213, 30-38.	1.1	3
60	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. <i>Cell Host and Microbe</i> , 2019, 26, 623-637.e8.	5.1	56
61	Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions. <i>Nature Communications</i> , 2019, 10, 78.	5.8	31
62	Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV. <i>Vaccines</i> , 2019, 7, 119.	2.1	5
63	Unidirectional Presentation of Membrane Proteins in Nanoparticle-Supported Liposomes. <i>Angewandte Chemie</i> , 2019, 131, 9971-9975.	1.6	0
64	Unidirectional Presentation of Membrane Proteins in Nanoparticle-Supported Liposomes. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 9866-9870.	7.2	9
65	Broadly Neutralizing Antibodies against HIV: Back to Blood. <i>Trends in Molecular Medicine</i> , 2019, 25, 228-240.	3.5	19
66	A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160. <i>ACS Chemical Biology</i> , 2020, 15, 2299-2310.	1.6	27
67	Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. <i>Immunity</i> , 2020, 53, 1230-1244.e5.	6.6	61
68	The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8. <i>Scientific Reports</i> , 2020, 10, 14313.	1.6	12
69	Neutralizing Antibodies Targeting HIV-1 gp41. <i>Viruses</i> , 2020, 12, 1210.	1.5	22
70	HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes. <i>Nature Chemical Biology</i> , 2020, 16, 529-537.	3.9	28
71	HIV-1 Envelope Spike MPER: From a Vaccine Target to a New Druggable Pocket for Novel and Effective Fusion Inhibitors. <i>ChemMedChem</i> , 2021, 16, 105-107.	1.6	5
72	Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses. <i>Journal of Virology</i> , 2021, 95, .	1.5	6

#	ARTICLE	IF	CITATIONS
73	HIV-1 Entry and Membrane Fusion Inhibitors. <i>Viruses</i> , 2021, 13, 735.	1.5	34
74	Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies. <i>ELife</i> , 2021, 10, .	2.8	15
75	Targeting Glycans of HIV Envelope Glycoproteins for Vaccine Design. <i>Chemical Biology</i> , 2017, , 300-357.	0.1	4
76	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. <i>PLoS ONE</i> , 2016, 11, e0157409.	1.1	44
77	Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells. <i>PLoS Pathogens</i> , 2015, 11, e1005233.	2.1	82
78	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. <i>PLoS Pathogens</i> , 2017, 13, e1006074.	2.1	33
79	Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. <i>PLoS Pathogens</i> , 2017, 13, e1006212.	2.1	58
80	Selection and immune recognition of HIV-1 MPER mimotopes. <i>Virology</i> , 2020, 550, 99-108.	1.1	4
82	Small-molecule HIV-1 entry inhibitors targeting the epitopes of broadly neutralizing antibodies. <i>Cell Chemical Biology</i> , 2022, 29, 757-773.	2.5	4
83	Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent. <i>Vaccines</i> , 2022, 10, 903.	2.1	3
84	Peptide Triazole Inhibitors of HIV-1: Hijackers of Env Metastability. <i>Current Protein and Peptide Science</i> , 2023, 24, 59-77.	0.7	4
86	Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 0, , .	1.5	0